Scandinavian Tobacco Group's Net Sales Exceed $13 Billion, XQS Nicotine Bags Continue Double-digit Growth

Mar.11.2025
Scandinavian Tobacco Group's Net Sales Exceed $13 Billion, XQS Nicotine Bags Continue Double-digit Growth
Scandinavian Tobacco Group A/S's 2024 net sales exceed 13 billion USD, driven by XQS nicotine pouch growth.

Key points:

 

1. In 2024, Scandinavian Tobacco Group's net sales exceeded 9 billion Danish krone ($13 billion) for the first time, with XQS nicotine pouches continuing to achieve double-digit growth.

 

2. The decrease in organic growth rate in the fourth quarter was due to the termination of distribution of third-party Next Generation Products (NGP) in the online business and a decrease in sales of handmade cigars in the United States.

 

3. Sales expectations for 2025 are expected to be impacted by major acquisitions and business adjustments.

 


 

Denmark's Scandinavian Tobacco Group A/S announced its full-year financial results for 2024 on March 6.

 

The report showed that net sales for 2024 increased by 5.4% to 9.2 billion Danish Krone ($1.3 billion), with an organic growth rate of 0.4%. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) before special items fell 1.3% to 2.1 billion Danish Krone ($0.3 billion), with an EBITDA profit margin of 22.6%. Free cash flow before acquisitions totaled 0.9 billion Danish Krone ($0.1 billion), while adjusted earnings per share were 13.7 Danish Krone ($2).

 

In Q4 2024, net sales rose 8.0% to 2.5 billion Danish Krone ($360 million), though organic growth declined by 1.0%. EBITDA before special items grew 15.4%, with an EBITDA margin of 24.3%. Free cash flow before acquisitions was 600 million Danish Krone ($88 million). 

 

The decline in organic growth was linked to the end of third-party NGP product distribution in the online business and lower sales of hand-rolled cigars in the U.S. XQS nicotine pouches saw double-digit growth, while machine-made cigarettes and tobacco products grew at a low single-digit rate.

 

The improvement in Q4 EBITDA was mainly driven by strong performance in tobacco products. However, profit margins were partially impacted by investments in growth drivers, including the machine-made cigarette business, and the termination of the NGP distribution business.

 

The company also predicts that the net sales for 2025 will be positively affected by the full year impact of the acquisition by Mac Baren, while the net sales reported will be negatively affected by the divestment of the NGP distribution business and the small lighter business in France that was discontinued since the third quarter of 2024. 

 

The expectations for 2025 include:

 

  • The report shows that net sales are between 9.2 billion and 9.7 billion Danish kroner (approximately $1.3 to $1.4 billion).
  • The EBITDA profit margin before special items is between 20-23%.
  • Free cash flow before acquisitions is between 0.8 billion and 1.1 billion Danish kroner (approximately $110 to $160 million).
  • The adjusted earnings per share range from 11.0-14.0.

 

CEO Niels Frederiksen stated that

 

"In 2024, we faced challenges but achieved a milestone with our first-ever net sales surpassing 9 billion Danish krone ($13 billion), and reached an EBITDA profit margin of 22.6%. During this period, we invested in growth-driving factors and the transformation of our core cigar business. In 2024, we returned 1.5 billion Danish krone ($2 billion) to shareholders and proposed a dividend of 8.50 Danish krone ($1.2) per share, marking the ninth consecutive year of dividend increase."

 

"We are pleased with the progress we have made towards achieving the goals set in our five-year strategic plan "Towards 2025." Since its launch in 2020, we have strengthened our brand presence in the United States and Europe, expanded our product portfolio to include next-generation products, and introduced an updated sustainability strategy. We have completed multiple acquisitions, our growth drivers have garnered attention, and we are building a more robust platform through numerous efforts in IT and digitization. We have made good progress in building a solid foundation, from which we can further develop."

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Product | PMI Japan Expands ZYN by IQOS Strength Portfolio With Strong Series, Increasing Lineup to 12 Products
Product | PMI Japan Expands ZYN by IQOS Strength Portfolio With Strong Series, Increasing Lineup to 12 Products
Philip Morris Japan (PMJ) has expanded the ZYN by IQOS oral tobacco pouch portfolio in Japan with four new ZYN Strong products, adding a third intensity level alongside the existing Low and Medium ranges. The Strong series first entered selected duty-free channels in Japan on July 1, 2026, before expanding to IQOS stores, the ZYN Online Store and selected tobacco retailers from August 18. The expansion increases the Japanese ZYN by IQOS lineup from eight to 12 products.
Aug.20
Product | BAT Japan Launches virto Bright Peach Click in Japan, Expanding glo Hilo’s Capsule-Based Flavor Portfolio
Product | BAT Japan Launches virto Bright Peach Click in Japan, Expanding glo Hilo’s Capsule-Based Flavor Portfolio
British American Tobacco Japan (BAT Japan) has introduced virto Bright Peach Click, a new heated tobacco stick designed for the glo Hilo system. The product expands the existing virto consumable lineup with a combination of tobacco, menthol and ripe peach flavors, featuring a capsule mechanism that releases additional fruit flavor when activated. The product launched in Japan on July 27, 2026, through glo official online channels, convenience stores and tobacco retailers.
Aug.03
JTI Proposes 25-Cent Irish Cigarette Tax Increase, Says It Could Raise €45 Million
JTI Proposes 25-Cent Irish Cigarette Tax Increase, Says It Could Raise €45 Million
Japan Tobacco International's Irish business has proposed a €0.25 tax increase on a pack of 20 cigarettes in its pre-Budget 2027 submission, below the €0.50-or-more increases typically imposed in recent Irish budgets. JTI says the proposal could generate around €45 million in additional Exchequer revenue while limiting further movement toward illicit and non-Irish-tax-paid tobacco. Revenue's existing estimate for a comparable €0.25 increase, including pro-rata rises on other tobacco products, is about €18 million for a full year.
JTI
Sep.18 by 2Firsts Perspectives
2FIRSTS EXCLUSIVE|China Breaks Up $6.8 Million Illegal Hookah Tobacco Operation as Market Expands
2FIRSTS EXCLUSIVE|China Breaks Up $6.8 Million Illegal Hookah Tobacco Operation as Market Expands
Chinese authorities have dismantled an illegal hookah tobacco operation worth more than 46 million yuan ($6.8 million), detaining five foreign suspects and seizing over 500,000 boxes of tobacco paste. The case comes as hookah expands across China’s nightlife sector and attracts overseas operators, including former vaping entrepreneurs. It also raises a central regulatory question: whether waterpipe tobacco will follow China’s private-sector e-cigarette licensing model or be reserved for the state tobacco system, as with nicotine pouches, in the years ahead.
Jul.31
JT’s Ploom Volumes Rise 43.5% as Cigarettes Anchor Its Transition
JT’s Ploom Volumes Rise 43.5% as Cigarettes Anchor Its Transition
JT’s Ploom heated-tobacco volumes rose 43.5% in the first half of 2026, while combustibles still represented about 97% of its tobacco volume and remained the main earnings base. In Japan, reduced-risk products now account for 48.7% of industry shipments, shifting competition from category adoption towards brand share, pricing and consumer retention. JT’s results offer a revealing case of a traditional tobacco company pursuing a prolonged, dual-track transformation.
JTI
Jul.30
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11